Edwards Lifesciences vs Regeneron Pharmaceuticals

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (78 vs 79)
Edwards Lifesciences logo

Edwards Lifesciences

LeaderHealthcare Tech

Enterprise

Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.

AI VisibilityBeta
Overall Score
B78
Category Rank
#41 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
74
Gemini
82

About

Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.

Full profile
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

LeaderHealthcare Tech

Enterprise

Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.

AI VisibilityBeta
Overall Score
B79
Category Rank
#29 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
76
Gemini
75

About

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.

Full profile

AI Visibility Head-to-Head

78
Overall Score
79
#41
Category Rank
#29
75
AI Consensus
73
stable
Trend
stable
73
ChatGPT
77
74
Perplexity
76
82
Gemini
75
81
Claude
85
76
Grok
74

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Integrations

Both integrate with
Edwards Lifesciences is classified as company. Regeneron Pharmaceuticals is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.